ClinicalTrials.gg
TerminatedNCT00322218Updated Jan 19, 2022Results posted

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

A Phase 3 interventional study of Zevalin in Lymphoma, Large Cell, Diffuse, sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 90 sites in 19 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
due to low recruitment rate that would have led to a long study duration.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Enrollment
257th of 963
68 · median 37
Started
2006
with 38 others
Phase 3
72 of 1,131
4 open now
Registered
362nd of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 257th largest by enrollment of the 963 interventional ones that give a count, is one of 39 that started in 2006, is one of 72 in phase 3, and was the 362nd registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This study treats patients with diffuse large B-cell lymphoma whose disease is in complete remission due to previous treatment with Cyclophosphamide Doxorubicin hydrochloride Vincristine Prednisolone- Rituximab (CHOP-R). Half of the patients received Zevalin and the other half receive no further anti-cancer treatment. The two patient groups compared to determine if Zevalin given after CHOP-R therapy provides greater benefits than receiving no additional anti-cancer therapy after CHOP-R.

Read the detailed description

The objectives of this study were to evaluate the efficacy and safety of the Zevalin study regimen compared with observation alone in patients with complete remission (CR or CRu) after first-line CHOP-R, the study was to include patients 60-years-of-age or older with histologically confirmed Ann Arbor stage II, III, or IV diffuse large B-cell lymphoma

End Points:

Primary endpoint: Overall survival (OS) Secondary endpoints: Disease-free survival (DFS), health-related quality of life (HRQL) as assessed by the patient using standard questionnaires .

Number of Patients :

A total of 400 patients (200 per arm) were planned to be enrolled.

  • In fact, 68 randomized patients (full analysis set; FAS) were analysed; 34 patients per each arm. The per-protocol set (PPS; 65 patients) comprised 33 patients allocated to the Zevalin arm and 32 patients allocated to the observation control arm.

Study Treatment :

The combination regimen with rituximab was designed in 2 steps as follows:

  • Day 1: Initial administration of 250 mg/m\^2 rituximab, followed immediately by administration of 185 megabecquerel (MBq) (5 millicurie [mCi]) of [111In]-ibritumomab tiuxetan (the latter one only in centers where biodistribution imaging or dosimetry was compulsory according to local law). In centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.
  • Day 7-9: Rituximab 250 mg/m\^2, followed immediately by [90Y]-ibritumomab tiuxetan 14.8 megabecquerel/kilograms (MBq/kg) (0.4 millicurie / kilogram [mCi/kg]) (maximum dose 1184 MBq) given as a slow intravenous (I.V.) push over 10 minutes. Two treatment days one week apart followed by a 12-week safety period.

Duration of Patient Participation:

Due to the sequential design, the total duration of this study was not fixed. Originally, the study was planned in a randomized, parallel-group, group sequential design.

Objective :

The primary objective of this study was an inferential comparison between the 2 randomized groups in terms of overall survival using a group sequential triangular test ,since the study was prematurely terminated the pre-planned group-sequential nature of the study design was not applicable statistical analyses. Actually, the prominent efficacy variables for the OS and DFS were analysed in the FAS (identical to the safety analysis set) and PPS using Kaplan Meier estimates by treatment group.

Study Design :

This study was designed as a prospective, multi-center, open label, randomized, two-armed, group-sequential Phase III study. The study was planned to consist of 2 stages: an interventional Stage 1 with Screening/Baseline, treatment, safety, and follow-up periods, and a non-interventional Stage 2 consisting of a long-term follow-up period (until completion of a median observation period of 5 years). This second stage of the study was to be started only if superiority of the Zevalin study regimen could be demonstrated in the preceding Stage 1.

Pharmacokinetics/Pharmacodynamic results: Not applicable

Extent of exposure:

All 34 patients randomized to the Zevalin arm were given 2 rituximab infusions(with a median dose of 425.0 mg at each of the 2 infusion time points).Three patients underwent radioimaging studies/dosimetry and therefore were administered [111In]-ibritumomab tiuxetan at Day 1. All but 1 patient received an infusion with [90Y]-ibritumomab tiuxetan following the second infusion of rituximab. The mean dose ranged from 765.9 -1197.0 MBq.

03

Conditions studied

  • Lymphoma, Large Cell, Diffuse
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, Ann Arbor stage II, III, or IV Diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma(REAL)/World Health Organization (WHO) classification .
  • Central pathology review confirming the DLBCL diagnosis and Cluster of differentiation 20 (CD20) positivity, and no evidence of DLBCL in bone marrow
  • treatment of DLBCL must have been 6 or 8 cycles of standard CHOP chemotherapy in combination with rituximab .
  • Complete remission(CR) or unconfirmed complete remission(CRu) according to the International Workshop Response Criteria for Non Hodgkins Lymphoma (NHL) described by Cheson et al and modified for this study after first-line treatment with CHOP-R. Computerised Tomography (CT) scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of CHOP-R. Applicability of the neck CT means that the patient had involvement of the neck region by palpation / physical examination at first diagnosis (pre-CHOP-R).
  • Central radiographic review of the CT scans from before and after first-line treatment with CHOP-R fulfilling the radiological requirements for CR/CRu
  • Patients 60 years of age or older at time of randomization
  • (PS) of 0 to 2 within 1 week of randomization
  • greater than or equal to 1.5 x 10\^9/L within 1 week of randomization
  • greater than or equal to 10 g/dL within 1 week of randomization
  • greater than or equal to 150 x 10\^9/L within 1 week of randomization
  • of 3 months or longer
  • Written obtained according to local guidelines

Exclusion criteria

Exclusion Criteria:

  • Presence of any other or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma
  • Prior radioimmunotherapy, radiation therapy, or any other NHL therapy except CHOP-R
  • Presence of gastric, central nervous system or testicular lymphoma at first diagnosis
  • Histological transformation of low-grade non-Hodgkin's lymphoma (NHL)
  • Known seropositivity for virus or surface antigen
  • Known history of (HIV) infection
  • Abnormal liver function: total > 1.5 x (ULN) or > 2.5 x ULN within 1 week of randomization
  • Abnormal renal function: serum creatinine > 2.0 x ULN within 1 week of randomization
  • Nonrecovery from the toxic effects of CHOP-R therapy
  • Known to murine or chimeric antibodies or proteins
  • Granulocyte Colony Stimulating Factor (G-CSF) or Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling
  • Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
  • Male and female patients of unwilling to practice effective during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment
  • Female patients who are pregnant or are currently breastfeeding
  • Treatment with drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy
  • Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery
  • Concurrent systemic use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment
  • Unwillingness or inability to comply with the protocol
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Zevalin

    Patients received Zevalin. Zevalin Therapeutic Regimen: Day 1: Initial administration of 250 mg/m\^2 rituximab, followed immediately by administration of 185 MBq of \[111In\]-ibritumomab tiuxetan ,in centers where centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone. - Day 7-9: Rituximab 250 mg/m\^2, followed immediately by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg given as a slow intravenous push over 10 minutes. Two treatment days one week apart were followed by a 12-week safety period.

    Drug: Zevalin

  • No intervention
    Observational

    Patients in this arm did not receive any reference therapy; they remained free of any anti-lymphoma therapy and were observed for relapse. This was non-interventional Stage consisting of a longterm follow-up period (until completion of a median observation period of 5 years).

Interventions

  • DrugIbritumomab tiuxetanStudies of Ibritumomab tiuxetanIbritumomab tiuxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion. The core treatment regimen in the Zevalin arm was: Day 1: Rituximab i.v. infusion 250 mg/m\^2 Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes.

    Also known as: Ibritumomab tiuxetan

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The primary analysis was based on the full analysis set (FAS). Actually, the prominent efficacy variable OS was analysed in the FAS (identical to the safety analysis set) and Per Protocol Set using Kaplan Meier estimates by treatment group. "Overall survival" was defined as the median time interval (in months)from randomization to death from any cause.This time-to-event variable was censored at the date of the last known follow-up visit (provided that the patient was still alive at that time).

    Time frame: 5 years or until patient dies or lost to follow up

Secondary outcomes

  1. Proportion of Participants With Disease Free Survival (DFS)

    DFS was analysed in the FAS (identical to the safety analysis set) and Per Protocol set using Kaplan Meier estimates by treatment group.Disease-free survival was defined as the median time interval (in months) from randomization to the date of relapse (as assessed by the investigator) or death from any cause. This time-to-event variable was also censored at the date of the last known follow-up visit (provided that the patient was still alive at that time).

    Time frame: 5 years or until patient disease progresses or lost to follow up

  2. The Health-related Quality of Life (HRQL)

    HRQL questionnaire consists of 27 questions each scores ranging from 0 - 4. The minimum score was 0 which is termed as 'worst imaginable health state' and the maximum score for a patient was 100 which is termed as 'best imaginable health state'. The descriptive classification defines health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension is subdivided into 3 levels: no problem, some or moderate problems, unable or extreme problems.

    Time frame: Up to Month 36

07

Results

Posted Jan 19, 2022
Limitations and caveats
The study was prematurely terminated after 68 patients had been randomized due to a low recruitment rate that would have led to an unacceptably long study duration.No safety concerns or lack of efficacy had led to the decision to cancel the study.

Participant flow

Diffuse large B-cell lymphoma (DLBCL) Patients at the age of at least 60 years and in complete remission (CR or CRu) after 6 or 8 cycles of a first-line treatment with Cyclophosphamide Doxorubicin hydrochloride Vincristine Prednisolone- Rituximab (CHOP-R) were enrolled in the study.

Participant flow — Overall Study
MilestoneZevalinObservation
Started3434
Per-protocol set3332
Completed3128
Not completed36
Withdrew: Death36

Outcome measures

PrimaryOverall Survival (OS)

The primary analysis was based on the full analysis set (FAS). Actually, the prominent efficacy variable OS was analysed in the FAS (identical to the safety analysis set) and Per Protocol Set using Kaplan Meier estimates by treatment group. "Overall survival" was defined as the median time interval (in months)from randomization to death from any cause.This time-to-event variable was censored at the date of the last known follow-up visit (provided that the patient was still alive at that time).

Time frame:
5 years or until patient dies or lost to follow up

No measurements were reported for this outcome.

SecondaryProportion of Participants With Disease Free Survival (DFS)

DFS was analysed in the FAS (identical to the safety analysis set) and Per Protocol set using Kaplan Meier estimates by treatment group.Disease-free survival was defined as the median time interval (in months) from randomization to the date of relapse (as assessed by the investigator) or death from any cause. This time-to-event variable was also censored at the date of the last known follow-up visit (provided that the patient was still alive at that time).

Time frame:
5 years or until patient disease progresses or lost to follow up
Reported as:
Number · proportion of participants
Proportion of Participants With Disease Free Survival (DFS)
proportion of participantsZevalinObservation
Proportion of Participants With Disease Free Survival (DFS)0.70580.7957
Statistical analysis
  • Zevalin vs Observation · Stratified Log-Rank Test · p = 0.8578
SecondaryThe Health-related Quality of Life (HRQL)

HRQL questionnaire consists of 27 questions each scores ranging from 0 - 4. The minimum score was 0 which is termed as 'worst imaginable health state' and the maximum score for a patient was 100 which is termed as 'best imaginable health state'. The descriptive classification defines health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension is subdivided into 3 levels: no problem, some or moderate problems, unable or extreme problems.

Time frame:
Up to Month 36
Reported as:
Mean · scores on a scale
The Health-related Quality of Life (HRQL)
scores on a scaleZevalinObservation
The Health-related Quality of Life (HRQL)84.2 ± 14.288.7 ± 12.6

Adverse events

Collected over Followed up until last anti-lymphoma treatment or 42 months whichever is longer.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zevalin—2/34 (5.9%)5/34 (14.7%)
Observation—1/34 (2.9%)1/34 (2.9%)
Most frequent serious events
Most frequent serious events
EventZevalinObservation
cytopeniaBlood and lymphatic system disorders2/341/34
Most frequent other events
Most frequent other events
EventZevalinObservation
Infections and manifestationsInfections and infestations5/341/34

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ZevalinObservationTotal
<=18 years000
Between 18 and 65 years369
>=65 years312859
Age, Continuous
Age, Continuous(years)ZevalinObservationTotal
Mean70.2 ± 4.668.8 ± 4.869.5 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)ZevalinObservationTotal
Female211940
Male131528
08

Study locations

90 sites
  • Research Site
    Mesa, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Scottsdale, Arizona, United States
  • Research site
    Bakersfield, California, United States
  • Research Site
    Berkeley, California, United States
  • Research Site
    Beverly Hills, California, United States
  • Research Site
    Burbank, California, United States
  • Research Site
    Duarte, California, United States
  • Research site
    Los Angeles, California, United States
  • Research site
    Newport Beach, California, United States
  • Research Site
    San Diego, California, United States
  • Research site
    Vallejo, California, United States
  • Research site
    Aurora, Colorado, United States
  • Research site
    Newark, Delaware, United States
  • Research site
    Saint Petersburg, Florida, United States
  • Research Site
    Coeur d'Alene, Idaho, United States
  • Research site
    Chicago, Illinois, United States
  • Research site
    Joliet, Illinois, United States
  • Research Site
    Morris, Illinois, United States
  • Research site
    Overland Park, Kansas, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research site
    Baltimore, Maryland, United States
  • Research site
    Boston, Massachusetts, United States
  • Research site
    Detroit, Michigan, United States
  • Research Site
    Rochester, Minnesota, United States
  • Research Site
    Saint Louis Park, Minnesota, United States
  • Research Site
    Commack, New York, United States
  • Research Site
    East Setauket, New York, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Aberdeen, South Dakota, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Norfolk, Virginia, United States
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Brugge, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Helsinki, Finland
  • Research Site
    Oulu, Finland
  • Research Site
    Creteil, France
  • Research Site
    Dijon, France
  • Research Site
    Lille Cedex, France
  • Research Site
    Limoges, France
  • Research Site, Cedax
    Lyon, France
  • Research Site
    Paris Cedex, France
  • Research Site
    Toulouse Cedex, France
  • Research Site
    Chemnitz, Germany
  • Research Site
    Jena, Germany
  • Research Site
    Karlsruhe, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Wurzburg, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Dublin, Ireland
  • Research Site
    Galway, Ireland
  • Research Site
    Bologna, Italy
  • Research Site
    Milan, Italy
  • Research Site
    Perugia, Italy
  • Research Site
    Pisa, Italy
  • Research Site
    Torino, Italy
  • Research Site, Yonsei
    Seoul, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Gdansk, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Poznan, Poland
  • Research Site
    Warsaw, Poland
  • Research Site
    Coimbra, Portugal
  • Research Site
    Lisbon, Portugal
  • Research Site
    Porto, Portugal
  • Research Site
    Singapore, Singapore
  • Research Site
    Madrid, Spain
  • Research Site
    Pamplona, Spain
  • Research Site
    Salamanca, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Malmo, Sweden
  • Research Site
    Uddevalla, Sweden
  • Research Site
    Umea, Sweden
  • Research Site
    Bern, Switzerland
  • Research Site
    St Gallen, Switzerland
  • Research Site
    Bangkok, Thailand
  • Research Site
    Leicester, United Kingdom
  • Research Site
    London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2022, 13 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2006
First posted
May 5, 2006
Start
May 2006
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 19, 2022
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00322218
Collaborators
Bayer
Responsible party
Sponsor
First posted
May 5, 2006
Start date
May 2006
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 19, 2022
Last update
Jan 19, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibritumomab tiuxetan

Start the discussion